What is a stock summary page? Click here for an overview.
Business Description
AIM ImmunoTech Inc
NAICS : 325414
SIC : 2836
ISIN : US42366C3016
Description
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate or unmet therapies. Its flagship products are Ampligen (rintatolimod) and Alferon N Injection (Interferon alfa). Ampligen is a double-stranded RNA (dsRNA) molecule being developed for globally important cancers, viral diseases, and disorders of the immune system. Ampligen is approved for commercial sale in the Argentine Republic for the treatment of severe Chronic Fatigue Syndrome (CFS).
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1.35 | |||||
| Equity-to-Asset | -0.15 | |||||
| Debt-to-Equity | -2.23 | |||||
| Debt-to-EBITDA | -0.18 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -76.39 | |||||
| Beneish M-Score | -3.72 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 8.7 | |||||
| 3-Year EPS without NRI Growth Rate | 1 | |||||
| 3-Year FCF Growth Rate | 3.6 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | -21.23 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 274.61 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 46.29 | |||||
| 9-Day RSI | 30.94 | |||||
| 14-Day RSI | 28.7 | |||||
| 3-1 Month Momentum % | -36.86 | |||||
| 6-1 Month Momentum % | -45.36 | |||||
| 12-1 Month Momentum % | -66.63 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.44 | |||||
| Quick Ratio | 0.44 | |||||
| Cash Ratio | 0.42 | |||||
| Days Sales Outstanding | 103.06 | |||||
| Days Payable | 73263.74 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -12.1 | |||||
| Shareholder Yield % | -117.89 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 81.77 | |||||
| Operating Margin % | -11630.59 | |||||
| Net Margin % | -10188.24 | |||||
| FCF Margin % | -9084.71 | |||||
| ROE % | -380.63 | |||||
| ROA % | -117.85 | |||||
| ROIC % | -271.41 | |||||
| 3-Year ROIIC % | 149.31 | |||||
| ROC (Joel Greenblatt) % | -2086.66 | |||||
| ROCE % | -316.04 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 9.93 | |||||
| EV-to-EBIT | -0.11 | |||||
| EV-to-EBITDA | -0.11 | |||||
| EV-to-Revenue | 10.79 | |||||
| EV-to-Forward-Revenue | 9.17 | |||||
| EV-to-FCF | -0.12 | |||||
| Price-to-GF-Value | 0.07 | |||||
| Price-to-Median-PS-Value | 0.08 | |||||
| Earnings Yield (Greenblatt) % | -909.09 | |||||
| FCF Yield % | -538.12 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:AIMI
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
AIM ImmunoTech Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.17 | ||
| EPS (TTM) ($) | -0.31 | ||
| Beta | 1.27 | ||
| 3-Year Sharpe Ratio | -0.89 | ||
| 3-Year Sortino Ratio | -1.29 | ||
| Volatility % | 34.91 | ||
| 14-Day RSI | 28.7 | ||
| 14-Day ATR ($) | 0.021504 | ||
| 20-Day SMA ($) | 0.06839 | ||
| 12-1 Month Momentum % | -66.63 | ||
| 52-Week Range ($) | 0.0251 - 0.469 | ||
| Shares Outstanding (Mil) | 72.29 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
AIM ImmunoTech Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
AIM ImmunoTech Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
AIM ImmunoTech Inc Frequently Asked Questions
What is AIM ImmunoTech Inc(AIMI)'s stock price today?
The current price of AIMI is $0.04. The 52 week high of AIMI is $0.47 and 52 week low is $0.03.
When is next earnings date of AIM ImmunoTech Inc(AIMI)?
The next earnings date of AIM ImmunoTech Inc(AIMI) is 2025-05-16 Est..
Does AIM ImmunoTech Inc(AIMI) pay dividends? If so, how much?
AIM ImmunoTech Inc(AIMI) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers